GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LifeTech Scientific Corp (HKSE:01302) » Definitions » YoY EBITDA Growth

LifeTech Scientific (HKSE:01302) YoY EBITDA Growth : -27.78% (As of Jun. 2024)


View and export this data going back to 2011. Start your Free Trial

What is LifeTech Scientific YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. LifeTech Scientific's YoY EBITDA Growth for the quarter that ended in Jun. 2024 was -27.78%.

LifeTech Scientific's EBITDA per Share for the six months ended in Jun. 2024 was HK$0.04.


LifeTech Scientific YoY EBITDA Growth Historical Data

The historical data trend for LifeTech Scientific's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LifeTech Scientific YoY EBITDA Growth Chart

LifeTech Scientific Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.92 34.85 20.22 5.61 -45.13

LifeTech Scientific Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.85 27.03 1.89 -121.28 -27.78

LifeTech Scientific YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

LifeTech Scientific's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(0.062-0.113)/ | 0.113 |
=-45.13 %

LifeTech Scientific's YoY EBITDA Growth for the quarter that ended in Jun. 2024 is calculated as:

YoY EBITDA Growth (Q: Jun. 2024 )
=(EBITDA per Share (Q: Jun. 2024 )-EBITDA per Share (Q: Jun. 2023 )) / | EBITDA per Share (Q: Jun. 2023 )) |
=(0.039-0.054)/ | 0.054 |
=-27.78 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LifeTech Scientific YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of LifeTech Scientific's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


LifeTech Scientific Business Description

Traded in Other Exchanges
Address
No. 22, Keji 12th Road South, LifeTech Scientific Building, High-tech Industrial Park, Nanshan District, Shenzhen, CHN, 518063
LifeTech Scientific Corp develops and manufactures also responsible for marketing of of advanced minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The firm operates in three areas: Structural heart diseases business; Peripheral vascular diseases business and Cardiac pacing and electrophysiology business. It generates maximum revenue from the Peripheral vascular diseases business segment. Geographically, it derives a majority of revenue from China.
Executives
Xie Yuehui 2201 Interest of corporation controlled by you
Xianjian Advanced Technology Limited 2101 Beneficial owner
Hhlr Advisors, Ltd. 2102 Investment manager
Bank Of Communications Trustee Limited 2301 Trustee
Xie Yuehui 2201 Interest of corporation controlled by you
Hhlr Fund, L.p. 2101 Beneficial owner
Hillhouse Capital Advisors, Ltd. 2102 Investment manager
Gaoling Fund, L.p. 2101 Beneficial owner

LifeTech Scientific Headlines

No Headlines